In addition, the relevance of these findings to human T1D had remained largely unexplored, despite the potential of FasL as a therapeutic target as it is not directly involved in T cell activation, and its modulation does not cause generalized immunosuppression (24). Here, FASLG is linked to type 1 diabetes mellitus.